Go to Top

Biotech News

Telik, Inc. (TELK): Telintra Granted Orphan Drug Designation by the FDA

Telik, Inc. (TELK) is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. Telik’s product candidates are: TELINTRA® (TLK199) is in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia TELCYTA® (TLK286) is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase …Read More

Rosetta Genomics (ROSG): Published Study of microRNA characteristics of CUP tumors

Rosetta Genomics is a leading molecular diagnostics company advancing molecular tests based on its proprietary microRNAs, and platform technologies. Following the launch of five cancer tests since the beginning of 2009, the Company is now working to develop additional tests in the cancer realm and in other fields. Rosetta Genomics today announced results from a …Read More

Savient Pharmaceuticals (SVNT): Election of Genzyme CEO Dr. David Meeker to Its Board of Directors

Savient Pharmaceuticals (NASDAQ: SVNT) operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary …Read More

Star Scientific (STSI): Positive Initial Results of ASAP Human Thyroid Health Study

Star Scientific, Inc. (STSI) announced the preliminary results of the Company’s ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study that analyses the impact of anatabine dietary supplementation on thyroid health. The study is a three-month, five-visit, double-blind, placebo-controlled study of the impact of anatabine dietary supplementation in humans with autoimmune disease of the thyroid. Initial results for …Read More

Inovio Pharmaceuticals (INO): Accelerate Development of Malaria Vaccines

Inovio Pharmaceuticals (INO) is a microcap biotech that is attempting to target the large indications of cancers and infectious diseases. The company’s novel pipeline is based on its SynCon® synthetic vaccine development platform. It is currently developing vaccines to address large areas of need, most notably cervical dysplasia/cancer, prostate cancer, hepatitis C virus, HIV, influenza, …Read More

Peregrine Pharmaceuticals (PPHM): Update on the Internal Review of Its Phase II Lung Cancer Trial

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. Company is pursuing multiple clinical programs in cancer with our lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned …Read More

EntreMed, Inc. (ENMD): Initiation of a Second Site for its ENMD-2076 Study

EntreMed, Inc. (ENMD) announced today the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC). Kathy Miller, MD, Associate Professor at the Melvin and Bren Simon Cancer Center at Indiana University serves as the investigator for the study. Indiana University joins the University of Colorado Cancer Center …Read More

Dehaier Medical Systems Ltd. (DHRM): Management Change

Dehaier Medical Systems Ltd. (DHRM) today announced that the interim CFO, Mr. Aileen Qi, has been appointed as Vice President of Finance and Operations, effective immediately. Mr. Charles Li has been appointed as the Company’s CFO. Mr. Li worked as senior auditor in KPMG Huazhen Beijing for two years with extensive experience in audit schemes …Read More

Keryx Biopharmaceuticals (KERX): Congress Delays Implementation of Oral-Only ESRD-Related Drugs

Keryx Biopharmaceuticals, Inc. (KERX) today announced that earlier this week Congress passed legislation known as the American Taxpayer Relief Act of 2012, which, among other things, delays by two years the implementation of oral-only end-stage renal disease (ESRD) related drugs, including phosphate binders, in the bundled ESRD prospective payment system, until January 1, 2016. The …Read More

Biogen (BIIB): Failure of the Lou Gehrig’s Disease Drug

Biogen (NASDAQ:BIIB) experimental drug for a rare disease that destroys the brain and spinal cord nerve cells failed in a company study. Biogen says it is ending its research program for the drug, dexpramipexole. The medicine was the in the late stages of testing for a treatment of amyotrophic lateral sclerosis, or ALS, which is …Read More